These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Caution regarding the choice of standard deviations to guide sample size calculations in clinical trials. Chen H; Zhang N; Lu X; Chen S Clin Trials; 2013 Aug; 10(4):522-9. PubMed ID: 23794405 [TBL] [Abstract][Full Text] [Related]
27. Power and sample size calculations for stochastic cost-effectiveness analysis. Briggs AH; Gray AM Med Decis Making; 1998; 18(2 Suppl):S81-92. PubMed ID: 9566469 [TBL] [Abstract][Full Text] [Related]
28. Methodology of superiority vs. equivalence trials and non-inferiority trials. Christensen E J Hepatol; 2007 May; 46(5):947-54. PubMed ID: 17412447 [TBL] [Abstract][Full Text] [Related]
29. Test Statistics and Confidence Intervals to Establish Noninferiority between Treatments with Ordinal Categorical Data. Zhang F; Miyaoka E; Huang F; Tanaka Y J Biopharm Stat; 2015; 25(5):921-38. PubMed ID: 24919157 [TBL] [Abstract][Full Text] [Related]
30. Adapting the sample size planning of a phase III trial based on phase II data. Wang SJ; Hung HM; O'Neill RT Pharm Stat; 2006; 5(2):85-97. PubMed ID: 17080765 [TBL] [Abstract][Full Text] [Related]
31. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Goodman SN; Berlin JA Ann Intern Med; 1994 Aug; 121(3):200-6. PubMed ID: 8017747 [TBL] [Abstract][Full Text] [Related]
32. [On the impact of sample size calculation and power in clinical research]. Held U Praxis (Bern 1994); 2014 Oct; 103(20):1197-201. PubMed ID: 25270749 [TBL] [Abstract][Full Text] [Related]
33. On sample size and inference for two-stage adaptive designs. Liu Q; Chi GY Biometrics; 2001 Mar; 57(1):172-7. PubMed ID: 11252594 [TBL] [Abstract][Full Text] [Related]
34. Two-stage sample size re-estimation based on a nuisance parameter: a review. Proschan MA J Biopharm Stat; 2005; 15(4):559-74. PubMed ID: 16022163 [TBL] [Abstract][Full Text] [Related]
35. On sample size determination in multi-armed confirmatory adaptive designs. Wassmer G J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570 [TBL] [Abstract][Full Text] [Related]
36. Adaptive methods: when and how should they be used in clinical trials? Porcher R; Lecocq B; Vray M; Therapie; 2011; 66(4):319-26, 309-17. PubMed ID: 21851793 [TBL] [Abstract][Full Text] [Related]
37. Adaptive designs from a Data Safety Monitoring Board perspective: Some controversies and some case studies. Turnbull BW Clin Trials; 2017 Oct; 14(5):462-469. PubMed ID: 28178849 [TBL] [Abstract][Full Text] [Related]
38. Mid-course sample size modification in clinical trials based on the observed treatment effect. Jennison C; Turnbull BW Stat Med; 2003 Mar; 22(6):971-93. PubMed ID: 12627413 [TBL] [Abstract][Full Text] [Related]
39. Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review. Hamasaki T; Evans SR; Asakura K J Biopharm Stat; 2018; 28(1):28-51. PubMed ID: 29083951 [TBL] [Abstract][Full Text] [Related]